Institutional investors purchased a net $251.2 thousand shares of STML during the quarter ended September 2013. This may signal that the smart money is gaining interest in this company as the 63.13% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
S.A.C. CAPITAL ADVISORS LP Bought 309.2 Thousand shares of Stemline Therapeutics Inc